RIPA-56

• UNSPSC Description:

  RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome[1].

• Target Antigen:

  RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/RIPA-56.html

• Purity:

  99.94

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  CCC(C)(C)C(N(CC1=CC=CC=C1)O)=O

• Molecular Weight:

  221.30

• References & Citations:

  [1]Ren Y, et al. Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-InteractingProtein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome. J Med Chem. 2017 Feb 9;60(3):972-986.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1956370-21-0